Gili Hart
Director/Board Member at ENLIVEX THERAPEUTICS LTD.
Net worth: 4 895 $ as of 2024-04-29
Gili Hart active positions
Companies | Position | Start | End |
---|---|---|---|
ENLIVEX THERAPEUTICS LTD. | Director/Board Member | 2013-12-31 | - |
Independent Dir/Board Member | 2013-12-31 | - | |
QUICKLIZARD LTD | Director/Board Member | 2021-02-20 | - |
Independent Dir/Board Member | 2021-02-20 | - | |
SpliSense Ltd.
SpliSense Ltd. Pharmaceuticals: MajorHealth Technology SpliSense Ltd. engages in the development of targeted therapies for genetic diseases based on splicing modulation treating the underlying root cause of the disease. The company was founded on November 10, 2016 and is headquartered in Jerusalem, Israel. | Director/Board Member | 2020-01-31 | - |
Chief Executive Officer | 2020-01-31 | - |
Career history of Gili Hart
Former positions of Gili Hart
Companies | Position | Start | End |
---|---|---|---|
COLLPLANT BIOTECHNOLOGIES LTD. | Director/Board Member | 2017-06-30 | 2023-07-04 |
Independent Dir/Board Member | 2017-06-30 | 2023-07-04 | |
Mitoconix Bio Ltd.
Mitoconix Bio Ltd. BiotechnologyHealth Technology Mitoconix Bio Ltd. develops novel therapeutics to improve mitochondrial health as a disease-modifying therapeutics for neurodegenerative diseases. The company was founded by Daria Mochly-Rosen in August 2016 and is headquartered in Ness Ziona, Israel. | Chief Executive Officer | 2016-12-31 | 2019-12-31 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | Chief Executive Officer | 2003-12-31 | 2016-12-31 |
Prolor Biotech Ltd.
Prolor Biotech Ltd. BiotechnologyHealth Technology Prolor Biotech Ltd. develops proprietary versions of already-approved therapeutic proteins. The private company is based in Nes Ziona, Israel. | Corporate Officer/Principal | 2008-12-31 | 2012-12-31 |
Enlivex Therapeutics Ltd. /Old/
Enlivex Therapeutics Ltd. /Old/ Medical SpecialtiesHealth Technology Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn’s disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company was founded by Dror Mevorach in 2005 and is headquartered in Jerusalem, Israel. | Director/Board Member | 2013-12-31 | - |
OPKO HEALTH, INC. | Corporate Officer/Principal | - | - |
Training of Gili Hart
Weizmann Institute of Science | Doctorate Degree |
Technion Institute | Undergraduate Degree |
Statistics
International
Israel | 10 |
United States | 2 |
Romania | 2 |
Operational
Director/Board Member | 5 |
Chief Executive Officer | 3 |
Independent Dir/Board Member | 3 |
Sectoral
Health Technology | 8 |
Consumer Services | 3 |
Health Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 4 |
---|---|
OPKO HEALTH, INC. | Health Services |
COLLPLANT BIOTECHNOLOGIES LTD. | Health Technology |
QUICKLIZARD LTD | Technology Services |
ENLIVEX THERAPEUTICS LTD. | Health Technology |
Private companies | 5 |
---|---|
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | Health Technology |
Enlivex Therapeutics Ltd. /Old/
Enlivex Therapeutics Ltd. /Old/ Medical SpecialtiesHealth Technology Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn’s disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company was founded by Dror Mevorach in 2005 and is headquartered in Jerusalem, Israel. | Health Technology |
Prolor Biotech Ltd.
Prolor Biotech Ltd. BiotechnologyHealth Technology Prolor Biotech Ltd. develops proprietary versions of already-approved therapeutic proteins. The private company is based in Nes Ziona, Israel. | Health Technology |
Mitoconix Bio Ltd.
Mitoconix Bio Ltd. BiotechnologyHealth Technology Mitoconix Bio Ltd. develops novel therapeutics to improve mitochondrial health as a disease-modifying therapeutics for neurodegenerative diseases. The company was founded by Daria Mochly-Rosen in August 2016 and is headquartered in Ness Ziona, Israel. | Health Technology |
SpliSense Ltd.
SpliSense Ltd. Pharmaceuticals: MajorHealth Technology SpliSense Ltd. engages in the development of targeted therapies for genetic diseases based on splicing modulation treating the underlying root cause of the disease. The company was founded on November 10, 2016 and is headquartered in Jerusalem, Israel. | Health Technology |
- Stock Market
- Insiders
- Gili Hart
- Experience